Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Brain Neoplasms 2Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 366Pemetrexed 308pembrolizumab 301Cisplatin 241Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 77atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × alovudine × Clear all
NCT00453362 2017-03-31

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

Genentech, Inc.

Phase 1/2 Completed
88 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡